HC Wainwright Reaffirms Buy Rating for Enlivex Therapeutics (NASDAQ:ENLV)

HC Wainwright restated their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a report released on Friday, Benzinga reports. They currently have a $6.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of Enlivex Therapeutics to a strong-buy rating in a report on Tuesday, August 27th.

Enlivex Therapeutics Trading Up 2.4 %

NASDAQ ENLV opened at $1.68 on Friday. Enlivex Therapeutics has a 12 month low of $1.15 and a 12 month high of $4.59. The company has a market capitalization of $35.97 million, a PE ratio of -1.21 and a beta of 1.03. The stock has a 50-day simple moving average of $1.35 and a 200 day simple moving average of $1.74.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings results on Friday, August 30th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. As a group, sell-side analysts predict that Enlivex Therapeutics will post -0.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enlivex Therapeutics

An institutional investor recently bought a new position in Enlivex Therapeutics stock. Armistice Capital LLC bought a new position in shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,700,571 shares of the company’s stock, valued at approximately $2,415,000. Armistice Capital LLC owned approximately 8.15% of Enlivex Therapeutics as of its most recent filing with the Securities and Exchange Commission. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.